Last reviewed · How we verify
Neural Stem Cells-expressing CRAd-S-pk7
At a glance
| Generic name | Neural Stem Cells-expressing CRAd-S-pk7 |
|---|---|
| Also known as | CRAd-S-pk7 loaded NSCs, NSC-CRAd-S-pk7, NSC-CRAd-S-pk7 Virotherapeutic, NSCs loaded with CRAd-S-pk7, SC-CRAd-Survivin-pk7 |
| Sponsor | City of Hope Medical Center |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Multiple Intracerebral Doses of Neural Stem Cell-Based Virotherapy (NSC-CRAd-S-pk7) for the Treatment of Recurrent High-Grade Gliomas (PHASE1)
- Repeated Neural Stem Cell Based Virotherapy for Newly Diagnosed High Grade Glioma (PHASE1)
- Neural Stem Cell Based Virotherapy of Newly Diagnosed Malignant Glioma (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: